Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Oxford BioMedica ( (GB:OXB) ).
Oxford Biomedica announced the appointment of Mr. Colin Bond as an Independent Non-Executive Director of OneSource Specialty Pharma Limited, pending shareholder approval. This appointment reflects OXB’s strategic efforts to strengthen its leadership and expand its influence in the global cell and gene therapy market.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £5.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s stock score is driven by its robust revenue growth and strategic expansions, offset by profitability challenges and high leverage. Technical indicators and valuation metrics provide mixed signals, while positive corporate developments support the outlook.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB is a pioneer in viral vectors, collaborating with leading pharmaceutical and biotechnology companies to provide expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. The company offers a range of technologies for viral vector manufacturing and has facilities in the UK, France, and the US.
Average Trading Volume: 210,067
Technical Sentiment Signal: Sell
Current Market Cap: £335.3M
For an in-depth examination of OXB stock, go to TipRanks’ Overview page.